ECE2007 Poster Presentations (1) (659 abstracts)
Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, University of Turin, Turin, Italy.
Semen quality and reproductive hormones may be affected in men with testicular neoplasia (TN) and lymphoproliferative disorders (LD). We evaluated these parameters before, 6, 12 and 24 months after the end of the oncological treatments in 60 patients with TN, and in 35 patients with LD. The patients were divided on the bases of the basal sperm concentration (A< and B≥ 10 million/ml). FSH, LH, testosterone (T) and inhibin B levels and sperm parameters were evaluated in all patients. The patients with TN showed a significant reduction of inhibin B levels and a significant increase of FSH levels 6 and 12 months after the end of the oncological treatments; LH levels showed a significant increase after 6 and 12 months only in patients of group A; T levels showed no variations after the treatment. Sperm concentration showed a significant reduction after 6 and 12 months only in patients of group B. The patients with LD showed a significant reduction of inhibin B levels after 6 and 12 months and a significant increase of FSH levels after 6, 12 and 24 months; LH and T levels showed no variations after the treatment. Sperm concentration showed a significant reduction after 6 and 12 months only in patients of group B. After 24 months reproductive hormones, except for FSH levels in LD, and sperm concentration showed no significant differences compared to basal levels. The other sperm parameters were not significantly affected by the treatment in all patients (TN and LD). In conclusion, the effect of the oncological treatments on sperm concentration is less evident in patients of group A, probably due to a predominant influence of the neoplastic condition. After 24 months we observed an improvement of the hormonal and seminal parameters in TN, except for a persistent iatrogenic effect in LD.